Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib
Hematological Oncology · 2024
DOI: 10.1002/hon.3294 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematological Oncology, 2024. Verfasst von Hana Dostálová und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Olomouc, Czech Republic. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Drug Resistance, Neoplasm, Pyrazoles, Pyrimidines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Univerzita Palackého v Olomouci, Grantová Agentura České Republiky.
Abstract (Originalsprache)
Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B‐cell malignancies. They target BTK, a key effector in the B‐cell receptor (BCR) signaling pathway, crucial for B‐cell survival and proliferation. The first‐in‐class irreversible BTK inhibitor, ibrutinib, was approved for various B‐cell malignancies but has limitations due to off‐target effects. Second‐generation inhibitors, such as acalabrutinib and zanubrutinib, offer improved selectivity and reduced side effects. However, resistance to BTK inhibitors, driven by BTK mutations, remains a challenge. Combinatorial therapies with PI3K inhibitors, immune checkpoint inhibitors, BH3 mimetics, and anti‐CD20 antibodies show promise in overcoming resistance. Noncovalent BTK inhibitors and proteolysis‐targeting chimeras (PROTACs) are emerging strategies with potential to combat resistance. Overall, advancements in BTK‐targeted therapies provide hope for improved outcomes in patients with B‐cell malignancies and a promising avenue to address drug resistance. Further research is needed to optimize combination therapies and identify optimal treatment regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Olomouc, Czech Republic.
ORCID-Profile: Vladimír Kryštof
Förderung
- Univerzita Palackého v Olomouci
- Grantová Agentura České Republiky
Zitieren
APA
Dostálová, H., & Kryštof, V. (2024). Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib. Hematological Oncology. https://doi.org/10.1002/hon.3294
Vancouver
Dostálová H, Kryštof V. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib. Hematological Oncology. 2024. doi:10.1002/hon.3294
BibTeX
@article{Dostlov2024,
author = {Dostálová, Hana and Kryštof, Vladimír},
title = {Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib},
journal = {Hematological Oncology},
year = {2024},
doi = {10.1002/hon.3294}
}
EUVIMED